Compare CLLS & HLXB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
Helix Acquisition Corp II is a Blank check company.